Orexigen(R) Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates (PR...

Monday October 6, 3:45 pm ET Empatic(TM) Shows Long-Term Weight Loss, Improved Quality of Life; Contrave(R) Reduces Rate of Metabolic Syndrome by Half - Data Presented at The Obesity Society Annual Scientific Meeting Offer Hope to 75 Million Americans Considered Obese - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX - News ), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that the company reviewed in an oral presentation at The Obesity Society Annual Scientific Meeting that the investigational drug, Empatic(TM) (zonisamide SR/bupropion SR), demonstrated up to 15% reduction in body weight of healthy obese people who completed 48-weeks of treatment in the absence of diet and exercise. In a second... [read full story]